Sign In
Buy AGLE
$12.01
+0 (+0%)
At Close: Feb 26, 2024
Aeglea BioTherapeutics Announces U.S. and EU Orphan Drug Designations for ACN00177 for the Treatment of Homocystinuria
08:30am, Monday, 26'th Oct 2020
AUSTIN, Texas, Oct. 26, 2020 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative
Aeglea BioTherapeutics to Present at World Orphan Drug Congress USA 2020
08:05pm, Tuesday, 18'th Aug 2020
AUSTIN, Texas, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovati
Aeglea BioTherapeutics Reports Second Quarter 2020 Financial Results and Corporate Highlights
12:30pm, Monday, 10'th Aug 2020
Pegzilarginase Showed Durable Clinical Response and Sustained Reduction in Plasma Arginine at 56 Week Analysis of Phase 1/2 Open-Label Extension Study Initiated Phase 1/2 Clinical Trial of ACN00177
Aeglea Bio Therapeutics (NASDAQ:AGLE) Downgraded by BidaskClub to “Sell”
05:14am, Thursday, 16'th Jul 2020
Aeglea Bio Therapeutics (NASDAQ:AGLE) was downgraded by equities researchers at BidaskClub from a “hold” rating to a “sell” rating in a research note issued to investors on Thursday, BidAskClu
How Should Investors React To Aeglea BioTherapeutics' (NASDAQ:AGLE) CEO Pay?
01:28pm, Monday, 13'th Jul 2020
Anthony Quinn has been the CEO of Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) since 2017, and this article will examine...
JPMorgan Chase & Co. Lowers Stock Position in Aeglea Bio Therapeutics Inc (NASDAQ:AGLE)
04:06am, Sunday, 05'th Jul 2020
JPMorgan Chase & Co. cut its position in shares of Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) by 32.5% during the first quarter, according to its most recent Form 13F filing with the SEC. The instituti
Were Hedge Funds Right About Buying Aeglea BioTherapeutics, Inc. (AGLE)?
04:05pm, Tuesday, 30'th Jun 2020
We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail invest
Here's Why Momentum Investors Will Love Aeglea Biotherapeutics (AGLE)
04:00pm, Monday, 29'th Jun 2020
Does Aeglea Biotherapeutics (AGLE) have what it takes to be a top stock pick for momentum investors? Let's find out.
Akebia Therapeutics (AKBA) Receives a Buy from Needham - Markets
02:54pm, Monday, 29'th Jun 2020
Needham analyst Chad Messer assigned a Buy rating to Akebia Therapeutics (AKBA – Research Report) today and set a price
Has Aeglea BioTherapeutics (AGLE) Outpaced Other Medical Stocks This Year?
03:30pm, Friday, 26'th Jun 2020
Is (AGLE) Outperforming Other Medical Stocks This Year?
Autolus Therapeutics (AUTL) Gets a Buy Rating from Needham - Markets
04:51pm, Thursday, 25'th Jun 2020
Needham analyst Chad Messer maintained a Buy rating on Autolus Therapeutics (AUTL – Research Report) today and set a price
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 23)
ACADIA Pharmaceuticals Inc...
Aeglea BioTherapeutics (AGLE) Catches Eye: Stock Jumps 5.1%
12:47pm, Tuesday, 23'rd Jun 2020
Aeglea BioTherapeutics (AGLE) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
The Daily Biotech Pulse: Sanofi Expedites COVID-19 Vaccine Timeline, Apyx Cleared For Market Expansion, Miragen's Positive Readout
12:00am, Tuesday, 23'rd Jun 2020
The following is a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 22)
ADC Therapeutics SA (...
Bank of New York Mellon Corp Purchases 4,763 Shares of Aeglea Bio Therapeutics Inc (NASDAQ:AGLE)
04:26am, Monday, 22'nd Jun 2020
Bank of New York Mellon Corp increased its position in shares of Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) by 5.3% in the first quarter, according to its most recent disclosure with the Securities & E
